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ABSTRACT
Background: HIV is the most important risk factor for
progression of latent tuberculosis infection (LTBI) to
active tuberculosis (TB). Detection and treatment of
LTBI is necessary to reduce the increasing burden of
TB in the UK, but a uniﬁed LTBI screening approach
has not been adopted.
Objective: To compare the effectiveness of a TB risk-
focused approach to LTBI screening in the HIV-positive
population against current UK National Institute for
Health and Clinical Excellence (NICE) guidance.
Design: Prospective cohort study.
Setting: Two urban HIV treatment centres in London,
UK.
Participants: 114 HIV-infected individuals with
deﬁned TB risk factors were enrolled prospectively as
part of ongoing studies into HIV and TB co-infection.
Outcome measures: The yield and case detection
rate of LTBI cases within the research study were
compared with those generated by the NICE criteria.
Results: 17/114 (14.9%, 95% CI 8.3 to 21.5) had
evidence of LTBI. Limiting screening to those meeting
NICE criteria for the general population (n¼43) would
have detected just over half of these, 9/43 (20.9%,
95% CI 8.3 to 33.5) and those meeting criteria for HIV
co-infection (n¼74) would only have captured 8/74
(10.8%, 95% CI 3.6 to 18.1) cases. The case detection
rates from the study and NICE approaches were not
signiﬁcantly different. LTBI was associated with the
presence of multiple TB risk factors (p¼0.002).
Conclusion: Adoption of a TB risk-focused screening
algorithm that does not use CD4 count stratiﬁcation
could prevent more cases of TB reactivation, without
changing the case detection rate. These ﬁndings
should be used to inform a large-scale study to create
uniﬁed guidelines.
INTRODUCTION
The incidence of disease caused by Mycobac-
terium tuberculosis (MTB) infection in the UK
has increased over the past 20 years and there
were 8483 notiﬁcations of tuberculosis (TB)
in 2010.
1 Co-infection with HIV was found
in 4.9% of UK active TB cases in 2010,
1 and
the total number of co-infection cases has
increased year on year in the European
region, from 9200 in 2007 to 13821 in 2009.
2
The prevention of co-infection cases rests
in part on treating latent tuberculosis inf-
ection (LTBI); however, there is little emp-
iric evidence guiding LTBI screening in the
HIV-positive population.
Treatment of LTBI reduces the risk of
progression to active TB,
3 which in the
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ARTICLE SUMMARY
Article focus
- HIV is the single most important risk factor for
the progression of LTBI to active TB.
- Despite this, the UK approach to screening for
LTBI in HIV co-infected individuals is not uniﬁed
as the evidence base is insufﬁcient.
- We hypothesised that LTBI screening in HIV co-
infected individuals required an approach
focused on TB risk factors that was broader
than recommended by NICE.
Key messages
- Screening strategies for LTBI in HIV co-infected
patients that focus on limited TB risk factors
(recent entrance from a TB endemic area or
history of TB contact) or limit screening to those
with a CD4 count of #500 cells/ml would detect
approximately half the total cases in this cohort.
- A TB risk-focused approach could aid in the
prevention of more cases of active TB and HIV
co-infection.
Strengths and limitations of this study
- This study addresses the utility of NICE guidance
for LTBI screening in the HIV co-infected
population.
- Numbers were relatively small, therefore a large
study is needed to better inform UK guidance on
LTBI screening in the HIV co-infected population.
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Open Access Researchsetting of HIV co-infection is more severe and associated
with extrapulmonary disease
4e6 and reduces the risk of
onward transmission and infection.
7 The complex
pharmacological interactions, risk of immune reconsti-
tution inﬂammatory syndrome and considerable pill
burden consequent upon treating both infections
contemporaneously are thus avoided. Preventing active
TB has potential cost savings; active TB treatment costs
£7095.08 more than 6 months of isoniazid therapy.
8
It is unknown whether the criteria for LTBI screening
should be the same as in the general population or
whether they should be tailored to the needs of the HIV-
infected. Recently published National Institute for
Health and Clinical Excellence (NICE) guidance
9
recommends that testing should be carried out in all
contacts of active TB and new entrants from high inci-
dence countries for the general population and the use
of single- or dual-step screening based on CD4 count for
the immunosuppressed. We postulated that the target
HIV-infected population for LTBI screening should be
broader because of the wealth of data demonstrating the
resurgence of TB due to the HIV epidemic.
10 11 HIV is
the single most important risk factor for progression of
LTBI to active disease and the risk of active TB increases
with immunosuppression
12 13 and is associated with MTB
infection and re-infection.
14 Therefore, an effective
screening strategy to detect and treat LTBI in those most
likely to become infected and to progress to active
disease is of public health interest.
Concerns regarding the sensitivity of both the tuber-
culin skin test (TST) and interferon-g (IFN-g) release
assays (IGRAs) in the HIV-infected population have
hindered their widespread use in HIV co-infection. The
TST has poor sensitivity in HIV-infected patients
15 and
poor speciﬁcity in those who have been BCG vacci-
nated
16 or those with a non-tuberculous mycobacterial
infection. It is a well-characterised assay, however, which
can improve targeting of chemoprophylaxis to those
most likely to beneﬁt.
17 New HIV guidelines suggest
using IGRAs rather than TST for LTBI screening,
18 and
NICE recommends IGRAs, with or without TST, depen-
dent on CD4 count.
9 IGRAs use the antigenic targets,
ESAT-6 and CFP-10, which are absent from BCG,
improving sensitivity and speciﬁcity for the diagnosis of
MTB infection.
16 19 There is some evidence that the
ELISpot platform is more sensitive in the setting of HIV
than the TST,
19 20 but more data are needed.
Current clinical practice for LTBI screening in the HIV
population is not uniform. Some units, as exempliﬁed by
the two large HIV clinics studied, screen a broader target
population for LTBI than the NICE criteria because of
the increased risk of active TB. Since this approach is not
based on empiric evidence, we examined the yield and
case detection rate of LTBI cases using both the criteria
recommended by NICE and by our broader research
study criteria. To our knowledge, this is the ﬁrst work to
speciﬁcally address the effectiveness of the NICE criteria
in the HIV-positive population.
METHODS
Subjects with HIV infection were prescreened by notes
review for LTBI risk factors and recruited from two
London HIV clinics (Imperial College Healthcare NHS
Trust and Northwest London Hospitals NHS Trust)
during January 2008eDecember 2010 as part of ongoing
studies into HIV and MTB co-infection. Radiological
ﬁndings, TST results and demographic data were
collected. A cut-off of $5 mm was used for TST posi-
tivity.
17 21 Patients with clinical (cough, fever, night
sweats, haemoptysis, weight loss), radiological or micro-
biological evidence of active TB and those with a history
of TB treatment or chemoprophylaxis were excluded.
Data on risk factors for TB were systematically recorded
as part of the parent study. A history of TB contact at any
time (recent or remote) was recorded.
Box 1 summarises current UK guidance for LTBI
screening in HIV.
Box 1 UK guidance for latent tuberculosis infection (LTBI)
screening with reference to HIV co-infection
National Institute for Health and Clinical Excellence guid-
ance on LTBI diagnosis
9
1. Tuberculosis (TB) contacts
Offer Mantoux testing in line with the Green Book to diag-
nose latent TB in people who are:
- household contacts (aged 5 years and older) of all
people with active TB.
- non-household contacts (other close contacts, eg, in
workplaces and schools).
Consider interferon-g testing for people whose Mantoux
testing shows positive results or in people for whom
Mantoux testing may be less reliable, eg, BCG-vaccinated
people.
If Mantoux testing is inconclusive, refer the person to a TB
specialist.
2. New entrants from high-incidence countries
Offer either an interferon-g test alone or a dual strategy in
people aged 16e35 years. For people aged 35 years or
older, consider the individual risks and beneﬁts of likely
subsequent treatment, before offering testing.
3. Immunocompromised
For people with HIV and CD4 counts less than 200 cells/ml,
offer an interferon-g test and a concurrent Mantoux test. If
either test is positive: perform a clinical assessment to
exclude active TB and consider treating latent TB infection.
For people with HIV and CD4 counts of 200e500 cells/ml,
offer an interferon-g test alone or an interferon-g test with
a concurrent Mantoux test. If either test is positive: perform
a clinical assessment to exclude active TB and consider
treating latent TB infection.
BHIVA 2011 guidelines
18
Consider country of origin, CD4 count and length of time on
highly active antiretroviral therapy. Close contacts of infec-
tious TB should be offered chemoprophylaxis. Interferon-g
release assays rather than tuberculin skin test are recom-
mended, although there is a call for more data.
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Screening for latent TB in HIV co-infectionUK guidance (NICE guidelines)
NICE recommends screening TB contacts and new
entrants (#5 years) from high TB incidence countries
(estimated incidence rate of 40/100000)
9 in those aged
16e35 years and to consider the risks and beneﬁts of
treatment before offering testing to those aged 35 years
or older. People with HIV who are in close contact with
people with sputum smear-positive respiratory TB should
have active disease excluded and then be given treat-
ment for latent TB infection. Treatment of LTBI should
be for people of any age who have HIV; therefore, an
upper age limit for LTBI screening was not imposed in
this study. Screening for immunosuppressed is recom-
mended as a dual step (IGRA and TST) for those with
a CD4 count <200 cells/ml and as single or dual step for
those with a CD4 count 200e500 cells/ml.
Research study screening approach
HIV-positive participants were classiﬁed as at risk of LTBI
according to a set of TB risk criteria. Those included had
a history of TB contact and/or were migrants from a TB
endemic country, regardless of date of entry into the UK
or had two or more additional risk factors (see table 1 for
empirical evidence on TB risk factors): travel to a TB
endemic area, smoking, more than occasional alcohol
intake, homelessness, injecting drug use, prison stay or
healthcare work.
Diagnosis of LTBI
All participants were screened with the research study
IGRA, an in-house IFN-g MTB ELISpot. Evidence of an
immunological response (positive IFN-g secretion) to
TB was made using the MTB region of difference 1
(RD 1) antigens, ESAT-6 and CFP-10, which are present
in the commercial T-Spot
.TB assay, and thus, the results
generated were considered to be equivalent to those
generated by the commercial assay. The test was
performed using pools of overlapping 15-mer peptides,
as described previously.
36 A positive response was
deﬁned as at least ﬁve spot-forming cells more than the
negative control well and at least twice the negative
control well. Where participants had been screened as
part of routine clinical work, this result was also used to
deﬁne cases of LTBI. The commercial IGRAs, T-Spot
.TB
or QuantiFERON
-TB GolddIn Tube (QFT), were
performed by the clinical diagnostic laboratory. TST data
were available for 20 cases but TST was not routinely
performed in accordance with BHIVA guidance. We
deﬁned LTBI as a positive response in any of the
screening assays (IGRA or TST).
Statistical analysis was performed using SPSS Statis-
tics (IBM) V.20 and Prism 5 GraphPad Software, Inc,
(La Jolla, California, USA). A Fisher’s exact test was used
to compare proportions. Signiﬁcance was assessed at the
5% and 1% level.
RESULTS
Research study screening approach
A total of 114 HIV-positive individuals were identiﬁed as
at risk of LTBI according to the study protocol. Median
age was 39 years (IQR 31.0e44.0), 77 (67.5%) were from
Table 1 Evidence for risk factors used in the study
Risk factor Evidence
Born in a TB endemic area HR for TB recurrence for foreign born 3.2 (95% CI 1.2 to 9.0)
22
Adjusted OR for TST positivity for LTBI in students 43.5 (95% CI 25.2 to 72.3)
23
Residence in a TB endemic area OR for QFT positivity in HIV patients 5.7 (95% CI 2.6 to 12.5)
24
TB contact OR for QFT positivity in HIV patients 4.9 (95% CI 2.0 to 11.8)
24
OR for QFT positivity in HIV patients 7.8 (p¼0.023)
25
Alcohol HR for incident TB in men drinking 50e99 g alcohol per day 1.2 (95% CI 1.1 to 1.3)
and $100 g alcohol per day 1.5 (95% CI 1.3 to 1.7)
26
Smoking HR for TB mortality in current male smokers 1.6 (95% CI 1.3 to 2.0) and incident
TB current male smokers 1.4 (95% CI 1.3 to 1.5)
26
Smoking associated with TB (weighted OR 2.4, 95% CI 1.71 to 3.39, p<0.001) and
a worse clinical picture, e.g., cavitation (OR 1.76, 95% CI 1.18 to 2.63)
27
Smoking associated with pulmonary TB (adjusted HR 2.87, 95% CI 2.00 to 4.11)
28
Pulmonary TB associated with smoking aOR (1.5)
29
Healthcare work TST conversion associated with nursing and ethnicity
30
TST conversion associated with place of healthcare work, e.g., infectious diseases
HR 1.94 (95% CI 1.50 to 2.49) in multivariate analysis
31
Risk of TB higher for healthcare workers than the general population
32
Illicit drug use Higher rates of TST positivity in crack smokers
33
HR for TB recurrence 2.9 (95% CI 1.3 to 6.4)
22
OR for QFT positivity in HIV patients 9.8 (p¼0.031)
25
Period of homelessness OR for QFT positivity in HIV patients 5.2 (p¼0.018)
25
Prison High prevalence of active TB in prisons in sub-Saharan Africa
34
Incidence rate ratio for LTBI 26.4 (IQR 13.0e61.8) and TB 23.0 (IQR 11.7e36.1)
35
Multiple risk factors OR in HIV patients for one or more risk factors 7.2 (2.9e18.2)
24
LTBI, latent tuberculosis infection; TB, tuberculosis; TST, tuberculin skin test; QFT, QuantiFERON TB test.
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Screening for latent TB in HIV co-infectionsub-Saharan Africa and 11 (9.6%) were from central and
southern America (table 2). The median (IQR) CD4
count was 412 (310e628) cells/ml and 72 (63.2%) were
prescribed highly active antiretroviral therapy (HAART)
at time of recruitment, 64 (56.1%) were women and 50
(43.9%) were men. Seventeen of 114 (14.9%, 95% CI 8.3
to 21.5) participants were diagnosed with LTBI in total.
Results of IGRA and TST are presented in table 3. The
local LTBI screening protocol detected nine (52.9%,
95% CI 26.5 to 79.3) cases and one had a negative screen
(TST and IGRA) in the clinic but a positive study
IGRA. Seven individuals (41.2%, 95% CI 15.1 to 67.3)
who had not been referred for clinical screening had
a positive research study IGRA. Therefore, the research
study approach increased the number of individuals
diagnosed with LTBI compared with current clinical
services, with an overall case detection rate of 14.9%
(table 4).
NICE guidance approach
A smaller proportion would have fulﬁlled NICE guid-
ance criteria for the general population (recent migrant
from a TB endemic area or TB contact). Screening
according to NICE guidance would have meant that 43/
114 (37.7%, 95% CI 28.6 to 46.8) would have been
eligible for screening of whom, 9/43 (20.9%, 95% CI 8.3
to 33.5) would have been diagnosed with LTBI (table 4).
The remaining 71 (62.3%, 95% CI 53.2 to 71.3) would
not be screened according to NICE guidance and 8/17
(47.1%, 95% CI 20.6 to 73.5) with LTBI would remain
undiagnosed. The detection rate was not signiﬁcantly
higher than with the research study approach
(p¼0.470), and the diagnostic yield was only 52.9% of all
LTBI cases detected.
When examining the criteria speciﬁcally for immuno-
suppressed patients suggested by NICE, 14/114 (12.3%,
95% CI 6.2 to 18.3) had a CD4 count of <200 cells/ml
and would have been eligible for dual-step screening and
60/114 (52.6%, 95% CI 43.3 to 61.9) had a CD4 count of
200e500 cells/ml and would have been eligible for
single- or dual-step screening. A remaining 40/114
(35.1%, 95% CI 26.1 to 43.4) had a CD4 count of greater
than 500 cells/ml and would not have been recom-
mended either approach. Of those with LTBI, none had
a CD4 count of <200 cells/ml, 8/17 (47.1%, 95% CI 21.6
to 73.5) had a CD4 count of 200e500 cells/ml and 9/17
(52.9%, 95% CI 26.5 to 79.3) had a CD4 count of
>500 cells/ml. Therefore, using this approach, fewer
than half the LTBI cases would have been detected, and
the detection rate would have fallen to 8/74 (10.8%,
95% CI 3.6 to 18.1), although this was not different from
the study approach (p¼0.512).
Risk factors for LTBI
A full TB risk history was taken at the time of recruit-
ment to the study. The TB risk factors used for selection
of subjects were chosen based on the available evidence
(table 1). On univariate analysis, more than occasional
alcohol intake (p¼0.008), injecting drug use (p¼0.023)
and two or more (p¼0.011) or three or more TB risk
factors (p¼0.002) were associated with LTBI (table 5). A
history of recent or remote TB contact or a history of
Table 2 Demographic characteristics of participants
eligible for LTBI screening
Demographic N[114 %
Age (years)
#25 12 10.5
26e35 32 28.1
36+ 70 61.4
Sex
Female 64 56.1
Male 50 43.9
Origin
Europe, North America,
Caribbean, Australia
13 11.4
Middle East, North Africa 2 1.8
Other Asia 8 7.0
Indian Subcontinent 3 2.6
Sub-Saharan Africa 77 67.5
Central and Southern America 11 9.6
BCG vaccinated
Yes 87 76.3
No 9 7.9
Unknown 18 15.8
TST (mm)
$5 6 5.3
<5 14 12.2
Not done 94 82.5
CD4 count
0e199 14 12.3
200e500 60 52.6
>500 40 35.1
Viral load
<50 49 43.0
50e1000 24 21.1
>1000 41 36.0
HAART therapy
Yes 72 63.2
No 42 36.8
HAART, highly active antiretroviral therapy; LTBI, latent
tuberculosis infection; TST, tuberculin skin test.
Table 3 IGRA (commercial or research assay) and TST
results
Positive
IGRA
Positive
TST
Total positive in
either or both
tests
IGRA only 10/94 NA 10/94 (10.6%)
TST and
IGRA
6/20 6/20 7/20* (35.0%)
*All participants underwent research IGRA screening, of the 20
participants who also underwent TST, discordance occurred in two
cases (one was positive who had a negative IGRA result and one
was negative who had positive IGRA result).
IGRA, interferon-g release assay; NA, not applicable; TST,
tuberculin skin test.
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Screening for latent TB in HIV co-infectionimmigration from a TB endemic area within 5 years was
not associated with LTBI. Multivariate analysis was not
performed as numbers were small. The presence of
multiple, rather than speciﬁc, TB risk factors was there-
fore most strongly associated with LTBI in this cohort.
DISCUSSION
The study has demonstrated that using currently avail-
able tools, a structured approach to screening in the
HIV-positive population detects LTBI in one in seven of
those with TB risk factors. Screening according to NICE
guidance using either general population guidance or
that speciﬁcally suggested for immunosuppressed indi-
viduals would only have detected half or fewer of these
LTBI cases. This is an important ﬁnding given that
recently published BHIVA guidance also recommends
screening stratiﬁed by CD4 count.
The case detection rate from the study approach was
not signiﬁcantly different from the rates generated by the
NICE approach. The number needed-to-be screened
increased, however, from 43 with NICE-speciﬁed risk
factors for the general population to 114. Although this
represents a 2.7-fold increase, which carries a cost impli-
cation, this would place a minimal additional strain on
resources. However, if NICE screening stratiﬁed by CD4
count were adopted, a total of 74 cases would have been
eligible for single- or dual-step screening. The estimated
costs of each test are: TST (£16.14); T-Spot
.TB (£55)
and QFT (£45)
8. In this study, the estimated additional
cost of screening those who did not fulﬁl NICE criteria
for immunosuppressed individuals (n¼40) would have
been £2200 for T-Spot
.TB alone and £2845.60 for a dual
TST and T-Spot
.TB screening strategy. These costs, in
addition to the cost of chemoprophylaxis (estimated at
£524.59, range £262.30e£1049.18 for 6 months Isoni-
azid
8), are small compared with the cost of treating one
case of active TB/HIV co-infection, where treatment of
TB alone has been estimated at £7619.67 (range
£3809.84e£15239.34).
8
Recent work has suggested that a single-step IGRA
approach is cost effective,
9 as is screening in the immi-
grant population.
37 In our study, TSTwas positive in one
individual with a negative IGRA. The increased risk of
both progression and expensive-to-treat extrapulmonary
or invasive disease in the HIV population would there-
fore be expected to improve the incremental cost-effec-
tiveness ratios and thus increase the cost-effectiveness of
screening for LTBI. In other clinical HIV cohorts, where
there is a higher proportion of sub-Saharan Africans (in
whom the prevalence of LTBI is highest), screening
would also be more cost effective. A full cost-effective-
ness analysis is required to determine whether single- or
dual-step testing would be most appropriate in this
population.
Table 4 Case detection rates for latent tuberculosis infection (deﬁned as positive TST and/or IGRA) for different screening
strategies
Screening approach Number tested Number positive
Case detection
rate (%)
Proportion of latent TB
infection identiﬁed (%)
Study 114 17 14.9 100.0
NICE general population 43 9 20.9 52.9
NICE immunosuppressed 74 8 10.8 47.1
IGRA, interferon-g release assay; NICE, National Institute for Health and Clinical Excellence; TST, tuberculin skin test.
Table 5 Comparison of risk factors for latent TB infection from those used in the study screening approach
TB risk factor
Diagnosed with
latent TB infection
No latent TB
infection
p
a n[17 (%) n[97 (%)
Born in a TB endemic country 15 88.2 83 85.6 NS
New entrant 4 23.5 13 13.4 NS
TB contact 5 29.4 23 23.7 NS
Travel to a TB endemic area 11 64.7 45 46.4 NS
Alcohol 7 41.2 12 12.4 0.008*
Smoking 6 35.3 22 22.7 NS
Healthcare work 3 17.6 8 8.2 NS
Injecting drug use 3 17.6 2 2.1 0.023y
Period of homelessness 1 5.9 4 4.1 NS
Prison 2 11.8 3 3.1 NS
$2 risk factors 17 100.0 69 71.1 0.011y
$3 risk factors 13 76.5 34 35.1 0.002*
ap Values are for Fisher’s exact test for each risk factor to compare those with and without LTBI.
*Signiﬁcance at 1% level.
ySigniﬁcance at 5% level.
NS, not signiﬁcant; TB, tuberculosis.
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Screening for latent TB in HIV co-infectionExtrapolating the study results to the wider UK setting,
in 2010, there were 23714 black Africans older than
14 years accessing care for HIV in the UK.
38 If we assume
14.9% (95% CI 8.3 to 21.5) would have LTBI (3533.4
cases), then approximately half would be diagnosed
according to the NICE criteria for either the general or
immunosuppressed population and 1766.7 cases would
remain undiagnosed. Estimates of those at risk of
developing active TB vary and include data from the pre-
HAART era; estimates of 5%e8% in 1 year have been
suggested,
33 9which would mean 88.3e141.3 at risk of
developing active TB in the subsequent 12 months.
Clinical observation in the HAART era suggests that this
estimate may be too high. Long-term observational data
are required to quantify this and to add to the limited
available evidence for the prognostic power of IGRAs.
40
The presence of multiple risk factors, rather than
particular risk factors, was most highly associated with
LTBI in our cohort. Since all patients with LTBI had two
or more risk factors, there is potential to reduce the
numbers screened by 25%. Studies in HIV-infected
populations have been carried out in Europe; in Spain,
41
Germany
42 and Denmark,
24 rates of IGRA positivity of
6.7%e9.3%, 18.9%e24% and 4.6%, respectively, were
found. Brock et al
24 showed that previous TB diagnosis,
history of exposure, long-term residence in a TB
endemic country and the presence of one risk factor or
more were associated with a positive QFN. Active TB was
associated with black African ethnicity, low CD4 count
and a shorter time on HAART in a UK study.
43
The diagnostic ability of the different assay platforms
has been previously studied.
19 44e46 There is evidence to
suggest that the ELISpot platform retains sensitivity in
HIV-infected individuals,
44 47e49 but there is no gold
standard test for LTBI and all methods may be affected
by HIV-induced immunosuppression. Despite this, the
use of the ELISpot platform in our study detected
a signiﬁcant rate of undiagnosed LTBI.
A pragmatic approach to screening for LTBI in HIV
co-infection is both necessary and possible. Screening
recent immigrants from endemic countries and TB
contacts would identify just over half of all cases and can
be recommended only as a minimum. Screening by
stratiﬁcation of CD4 count would also only detect less
than half the cases. Expanding the screening criteria to
include multiple risk factors, which would, using
currently available assays double the yield without
altering the case detection rate, should be considered as
an alternative strategy.
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